SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02419287

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.

NCT02419287 Anaplastic Large Cell Lymphoma, ALK-Positive
MeSH: Lymphoma Lymphoma, Large-Cell, Anaplastic
HPO: Anaplastic large-cell lymphoma Lymphoma

1 Interventions

Name: crizotinib

Type: Drug

crizotinib


Primary Outcomes

Measure: objective response rates (ORR) in subjects with ALK+ lymphomas resistant or refractory to standard cytotoxic treatment, according to RECIST 1.1 criteria.

Time: the entire duration of the study (5 years)

Measure: Duration ORR

Time: the entire duration of the study (5 years)

Secondary Outcomes

Measure: Progression free survival (PFS) in ALK+ lymphoma patients treated with crizotinib, that are resistant or refractory to standard cytotoxic treatment.

Time: the entire duration of the study (5 years)

Measure: Number of patients with adverse events after crizotinib treatment

Time: the entire duration of the study (5 years)

Measure: Quality of Life (QoL) in this population of patients using the the EORTC - C30 Quality of Life questionnaire

Time: the entire duration of the study (5 years)

Measure: Overall survival (OS) in ALK+ lymphoma patients treated with crizotinib

Time: the entire duration of the study (5 years)

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 I1171N

Although crizotinib shows activity, relapses occur typically within 5 months after starting treatment and were supported by mutations like I1171N. --- I1171N ---



HPO Nodes


HPO:
Anaplastic large-cell lymphoma
Lymphoma
Genes 133
ATM KRAS CD19 IGH DDX41 BCL10 BIRC3 FOXP1 MS4A1 TP63 RAG1 LIG4 NFKB2 MSH6 TERC RECQL4 NTHL1 WIPF1 CTC1 LYST NOP10 RASGRP1 TNFRSF1B XRCC4 PRKCD NHP2 MAGT1 TNFRSF13B IGH RMRP RUNX1 CTLA4 DCLRE1C FAS ICOS RNF43 NSUN2 XIAP IL7R CASP10 BCL6 CDKN2A ATM IL2RG RTEL1 PARN NBN KIT TNFRSF13C TCF4 ICOS TNFSF12 CHEK2 USB1 CD19 CR2 NRAS MSH2 WAS BCL10 CASP10 MYD88 COL14A1 PRKCD TNFRSF13B MYC MDM2 SH2D1A CCND1 BCL10 CFTR CD27 PGM3 TCF4 CHD7 IGH LIG4 BLM BCL2 TET2 HLA-DRB1 PRSS1 NPM1 KIF11 ITK WRAP53 RAD54B TINF2 FAS DKC1 APC CD81 LIG4 BLM CD28 DKC1 AAGAB RAG2 TNFRSF1B MLH1 TNFRSF13C DNASE1L3 NFKB1 PMS2 ASXL1 IL2RG PRF1 PTEN MALT1 RAD54L CTLA4 CD28 PNP SRSF2 TNFSF12 STAT3 POLE ADA CR2 ADA FASLG PIK3R1 TP53 CTRC ZAP70 MYD88 RB1 RMRP SPINK1 TERT KLHDC8B NBN RHOH